Digestive Diseases and Sciences

, Volume 46, Issue 11, pp 2314–2321 | Cite as

Inhibition of β-Catenin Translocation in Rodent Colorectal Tumors: A Novel Explanation for the Protective Effect of Nonsteroidal Antiinflammatory Drugs in Colorectal Cancer

  • Wendy A. Brown
  • Stewart A. Skinner
  • Daphne Vogiagis
  • Paul E. O'brien


In a rodent colorectal cancer model, nonsteroidal antiinflammatory drugs reduce tumor mass by increasing the rate of tumor cell apoptosis and decreasing proliferation. We have examined β-catenin as a potential target for these agents in colorectal cancer. Carcinogen-treated rats were treated for 23 weeks with a range of nonsteroidal antiinflammatory drugs. Control animals received vehicle alone. Intracellular β-catenin was examined using immunohistochemistry. In tumors from untreated animals, staining was seen in the cytoplasm and nucleus (median 24% of nucleii). The frequency of nuclear β-catenin staining correlated directly with the volume of tumor and inversely with the rate of apoptosis. In tumors from treatment groups, the cytoplasmic staining for β-catenin was unchanged; however, nuclear staining was absent except in the celecoxib group, where it was reduced to a median of 14%. Colorectal tumors from animals treated with NSAIDs show reduced levels of nuclear β-catenin immunoreactivity.

β-catenin nonsteroidal antiinflammatory drugs colorectal cancer immunohistochemistry apoptosis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kune GA, Kune S, Watson LF: Colorectal cancer risk, chronic illnesses, operations and medications: Case control results from the Melbourne Colorectal Cancer Study. Cancer Res 48:4399–4404, 1988Google Scholar
  2. 2.
    Thun MJ, Calle EE, Namboodiri MM, et al: Risk factors for fatal colon cancer in a large prospective study. J Natl Cancer Inst 84:1491–1500, 1992Google Scholar
  3. 3.
    Thun MJ, Namboodiri MM, Calle EE, et al: Aspirin use and risk of fatal cancer. Cancer Res 53:1322–1327, 1993Google Scholar
  4. 4.
    Giovannucci E, Egan KM, Hunter DJ, et al: Aspirin and the risk of colorectal cancer in women. N Engl J Med 333:609–614, 1995Google Scholar
  5. 5.
    Skinner SA, Penney AG, O'Brien PE: Sulindac Inhibits the rate of growth and appearance of colon tumors in the rat. Arch Surg 126:1094–1096, 1991Google Scholar
  6. 6.
    Charalambous D, Farmer KCR, O'Brien PE: Sulindac and indomethacin inhibit formation of aberant crypt foci in the colons of dimethyl hydrazine treated rats. J Gastroenterol Hepatol 11:88–92, 1996Google Scholar
  7. 7.
    Vane JR: Towards a better aspirin. Nature 367:215–216, 1994Google Scholar
  8. 8.
    Vane JR: NSAIDs, COX-2 inhibitors, and the gut. Lancet 346:1105–1106, 1995Google Scholar
  9. 9.
    Chiu C-H, McEntee M, Whelan J: Sulindac causes rapid regression of pre-existing tumours in Min/+ mice independent of prostaglandin biosynthesis. Cancer Res 57:4267–4273, 1997Google Scholar
  10. 10.
    Charalambous D, Skinner S, O'Brien P: Sulindac inhibits colorectal tumour growth, but not prostaglandin synthesis in the rat. J Gastroenterol Hepatol 13:1195–1200, 1998Google Scholar
  11. 11.
    Charalambous D, O'Brien PE: Inhibition of colon cancer precursors in the rat by sulindac sulphone is not dependent on inhibition of prostaglandin synthesis. J Gastroenterol Hepatol 11:307–310, 1996Google Scholar
  12. 12.
    Piazza GA, Alberts DS, Hixson LJ, et al: Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 57:2909–2915, 1997Google Scholar
  13. 13.
    Sano H, Kawahito Y, Wilder RL, et al: Expression of cyclooxygenase-1 and-2 in human colorectal cancer. Cancer Res 55:3785–3789, 1995Google Scholar
  14. 14.
    DuBois RN, Radhika A, Reddy BS, et al: Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumours. Gastroenterology 110:1259–1262, 1996Google Scholar
  15. 15.
    Kargman SL, O'Neill GP, Vickers PJ, et al: Expression of prostaglandin G/H synthase-1 and-2 protein in human colon cancer. Cancer Res 55:2556–2559, 1995Google Scholar
  16. 16.
    Brown W, Skinner S, Vogiagis D, et al: Chemoprevention of colorectal cancer-a comparative study of efficacy and gastrotoxicity of NSAIDs. J Gastroenterol Hepatol 13(suppl):A128, 1998Google Scholar
  17. 17.
    Oshima M, Dinchuk J, Kargman SL, et al: Suppression of intestinal polyposis in APC-716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87:803–809, 1996Google Scholar
  18. 18.
    Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61:759–767, 1990Google Scholar
  19. 19.
    Sparks AB, Morin PJ, Vogelstein B, et al: Mutational analysis of the APC/β-Catenin/Tcf pathway in colorectal cancer. Cancer Res 58:1130–1134, 1998Google Scholar
  20. 20.
    Binder HJ: The gatekeeper has many keys: Dissecting the function of the APC gene. Gastroenterology 113:2009–2012, 1997Google Scholar
  21. 21.
    Iwao K, Nakamori S, Kameyama M, et al: Activation of the β-catenin gene by interstitial deletions involving exon 3 in primary colorectal carcinomas without adenomatous polyposis coli mutations. Cancer Res 58:1021–1026, 1998Google Scholar
  22. 22.
    Samowitz WS, Powers MD, Spirio LN, et al: β-Catenin mutations are more frequent in small colorectal adenomas than in larger adenomas and invasive carcinomas. Cancer Res 59:1442–1444, 1999Google Scholar
  23. 23.
    Herter P, Kuhnen C, Muller KM, et al: Intracellular distribution of B-catenin in colorectal adenomas, carcinomas and Peutz-Jeghers polyps. J Cancer Res Clin Oncol 125:297–304, 1998Google Scholar
  24. 24.
    Rubinfeld B, Albert I, Porfiri E, et al: Binding of GSK3B to the APC-B-catenin complex and regulation of complex assembly. Science 272:1023–1026, 1996Google Scholar
  25. 25.
    Rubinfeld B, Souza B, Albert I, et al: Association of the APC gene product with β-catenin. Science 262:1731–1734, 1993Google Scholar
  26. 26.
    Behrens J, von Kries JP, Kuhl M, et al: Functional interaction of β-catenin with the transcription factor LEF-1. Nature 382:638–642, 1996Google Scholar
  27. 27.
    Morin PJ, Sparks AB, Korinek V, et al: Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 275:1787–1790, 1997Google Scholar
  28. 28.
    Shapiro L: The multi-talented β-catenin makes its first appearance. Structure 5:1265–1268, 1997Google Scholar
  29. 29.
    Roose J, Huls G, van Beest M, et al: Synergy between tumour suppressor APC and the β-catenin-Tcf4 target Tcf1. Science 285:1923–1926, 1999Google Scholar
  30. 30.
    He T, Sparks A, Rago C, et al: Identification of c-MYC as a target of the APC pathway. Science 281:1509–1512, 1998Google Scholar
  31. 31.
    Shtutman M, Zhurinsky J, Simcha I, et al: The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 96:5522–5527, 1999Google Scholar
  32. 32.
    Howe LR, Subbaramaiah K, Chung WJ, et al: Transcriptional activation of cyclooxygenase-2 in Wnt-1 transformed mouse mammary epithelial cells. Cancer Res 59:1572–1577, 1999Google Scholar
  33. 33.
    Crawford HC, Fingleton BM, Rudolph-Owen LA, et al: The metalloproteinase matrilysin is a target of B-catenin transactivation in intestinal tumors. Oncogene 18:2883–2891, 1999Google Scholar
  34. 34.
    Maltzman T, Whittington J, Driggers L, et al: AOM-induced mouse colon tumors do not express full-length APC protein. Carcinogenesis 18:2435–2439, 1997Google Scholar
  35. 35.
    Takahashi M, Fukuda K, Sugimura T, et al: β-Catenin is frequently mutated and demonstrates altered cellular location in azoxymethane-induced rat colon tumours. Cancer Res 58:42–46, 1998Google Scholar
  36. 36.
    Meade EA, Smith WL, DeWitt DL: Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 268:6610–6614, 1993Google Scholar
  37. 37.
    Mitchell J, Akarasereenont P, Thiemermann C, et al: Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 90:11693–11697, 1994Google Scholar
  38. 38.
    Donnelly MT, Hawkey CJ: COX-2 inhibitors-a new generation of safer NSAIDs? Aliment Pharmacol Ther 11:227–236, 1997Google Scholar
  39. 39.
    Gierse JK, Hauser SD, Creely DP, et al: Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem J 305:479–484, 1995Google Scholar
  40. 40.
    Kargman S, Wong E, Greig GM, et al: Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and-2 in intact cells. Biochem Pharmacol 52:1113–1125, 1996Google Scholar
  41. 41.
    Masferrer JL, Isakson PC, Seibert K: Cyclooxygenase-2 inhibitors-a new class of anti-inflammatory agents that spare the gastrointestinal tract. Gastroenterol Clin North Am 25:363–372, 1996Google Scholar
  42. 42.
    Reddy BS, Rao CV, Seibert K: Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 56:4566–4569, 1996Google Scholar
  43. 43.
    Brown W, Skinner S, Malcontenti-Wilson C, Vogiagis D, O'Brien P: Nonsteroidal antiinflammatory drugs with varying activity against either cyclooxygenase-1 or cyclooxygenase-2 inhibit colorectal cancer in a DMH rodent model by inducing apoptosis and inhibiting cell proliferation. Gut (in press)Google Scholar
  44. 44.
    Brown WA, Skinner SA, Malcontenti-Wilson C, et al: NSAIDs with varying activity against the two cyclooxygenase isoforms induce apoptosis and reduce proliferation in a rodent colon cancer model. J Gastroenterol Hepatol 14:A179, 1999Google Scholar
  45. 45.
    Rigas, Schiff: Is inhibition of cyclooxygenase required for the chemopreventive effect of NSAIDs in colon cancer? A model reconciling the current contradiction. Med Hypotheses 54:210–215, 2000Google Scholar
  46. 46.
    Yin MJ, Yamomoto Y, Gaynor RB: The anti-inflammatory agents aspirin and salicylate inhibit the activity of I kappa B kinase-beta. Nature 396:77–80, 1998Google Scholar
  47. 47.
    He T-C, Chan TA, Vogelstein B, Kinzler KW: PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99:335–345 1999Google Scholar
  48. 48.
    Chang WC, Pfeiffer GR, Cooper HS, et al: Sulindac sulfone modulates the expression and cellular location of β-catenin in human colon carcinoma cells. Gastroenterology 116:G1695 1999Google Scholar
  49. 49.
    McEntee M, Chiu C-H, Whelan J: Relationship of β-catenin and Bc1-2 expression to sulindac-induced regression of intestinal tumors in Min mice. Carcinogenesis 20:635–640, 1999Google Scholar
  50. 50.
    Nigg EA: Nucleocytoplasmic transport: Signals, mechanisms and regulation. Nature 386:779–787, 1997Google Scholar

Copyright information

© Plenum Publishing Corporation 2001

Authors and Affiliations

  • Wendy A. Brown
    • 1
  • Stewart A. Skinner
    • 1
  • Daphne Vogiagis
    • 1
  • Paul E. O'brien
    • 1
  1. 1.Monash University Department of SurgeryAlfred HospitalMelbourneAustralia

Personalised recommendations